<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03424577</url>
  </required_header>
  <id_info>
    <org_study_id>H3B-6527-A001-001</org_study_id>
    <nct_id>NCT03424577</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Food-Effect of H3B-6527</brief_title>
  <official_title>A Randomized Phase 1 Food-Effect Study of H3B-6527 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>H3 Biomedicine Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be conducted to determine the effect of food on the relative bioavailability
      of H3B-6527 following administration of a H3B-6527 capsule with and without a meal.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 27, 2017</start_date>
  <completion_date type="Actual">January 27, 2018</completion_date>
  <primary_completion_date type="Actual">January 27, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean area under the plasma-concentration time curve from time 0 through the last measurable concentration (AUC0-t) of H3B-6527</measure>
    <time_frame>Days 1 and 5: Pre-dose, and 1, 2, 3, 4, 8, 12, and 16 hours postdose. Days 2 and 6: 24 and 36 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean area under the plasma concentration-time of maximum observed last measurable concentration (tmax) of H3B-6527</measure>
    <time_frame>Days 1 and 5: Pre-dose, and 1, 2, 3, 4, 8, 12, and 16 hours postdose. Days 2 and 6: 24 and 36 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean maximum observed plasma concentration (Cmax) of H3B-6527</measure>
    <time_frame>Days 1 and 5: Pre-dose, and 1, 2, 3, 4, 8, 12, and 16 hours postdose. Days 2 and 6: 24 and 36 hours postdose</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Healthy Participants</condition>
  <arm_group>
    <arm_group_label>H3B-6527</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy male participants will be randomly assigned to 1 of 2 possible treatment sequences: either H3B-6527 capsule with food on Day 1 and H3B-6527 capsule without food on Day 5 (treatment sequence fed/fasted), or H3B-6527 capsule without food on Day 1 and H3B-6527 capsule with food on Day 5 (treatment sequence fasted/fed).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>H3B-6527</intervention_name>
    <description>Oral capsule</description>
    <arm_group_label>H3B-6527</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-smoking, healthy male between the ages of 18 and 55 years old

          -  Body mass index (BMI) &gt;18 and â‰¤ 29 kilograms per meters squared (kg/m^2)

          -  Participants who have not had a successful vasectomy and are partners of women of
             childbearing potential must use a medically effective method of contraception with
             their partner during the study period through 30 days after the last dose of study
             drug. No sperm donation is allowed during the study period or for 30 days after study
             drug discontinuation

        Exclusion Criteria:

          -  Participants with clinically significant heart, liver, gastrointestinal, kidney, lung,
             hormonal, blood, nerve or psychiatric disease or history of gastrointestinal surgery
             or gall bladder removal that could effect the uptake, distribution or elimination of
             H3B-6527

          -  Participants with a history of drug or alcohol misuse within 6 months prior to
             screening or a positive urine drug test

          -  Participants diagnosed with acquired immune deficiency syndrome (AIDS), or who test
             positive for human immunodeficiency virus (HIV), Hepatitis B (HBV), or Hepatitis C
             (HCV)

          -  Participated in another clinical trial less than 4 weeks prior to dosing or is
             currently enrolled in another clinical trial

          -  Received blood products within 4 weeks, or donated blood within 8 weeks, or donated
             plasma within 1 week prior to the first dose

          -  Participants used any prescription or over-the-counter drugs within 2 weeks prior to
             the first dose
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Worldwide Clinical Trials</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2018</study_first_submitted>
  <study_first_submitted_qc>February 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 7, 2018</study_first_posted>
  <last_update_submitted>February 1, 2018</last_update_submitted>
  <last_update_submitted_qc>February 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>H3B-6527</keyword>
  <keyword>Healthy Participants</keyword>
  <keyword>Pharmacokinetics</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

